GSK Will Submit Data To FDA On Lexiva’s Comparability To Kaletra
This article was originally published in The Pink Sheet Daily
Results of a GSK/Vertex head-to-head clinical study indicate that Lexiva plus ritonavir is comparable to Abbott’s Kaletra in treatment-naive HIV patients.
You may also be interested in...
GSK/Vertex’s post-marketing study found that proton pump inhibitor use does not lessen the protease inhibitor’s efficacy.
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
The company released an annual pricing report, showing that Sanofi's US average net prices declined for the fifth year in a row.